A Study of ARC-02 in B-cell NHL
ConditionB-cell Non Hodgkin Lymphoma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorTaiho Oncology, Inc.
About this trial
This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.
Eligibility criteria
Qualifiers
Follicular lymphoma (FL), Grades 1 through 3B
Marginal zone lymphoma (MZL)
Mantle cell lymphoma (MCL)
Diffuse large B-cell lymphoma (DLBCL)
Disqualifiers
Receiving an investigational product or participating in any other type of medical research judged not to be compatible with this study.
Grade > 1 neuropathy
History of interstitial lung disease (ILD)/pneumonitis requiring treatment or any evidence of active ILD/pneumonitis.
Chemotherapy, radiotherapy, small molecule, investigational, and biologic agents (including CD79b-directed agents) within 28 days (or at least 5 half-lives, whichever is shorter), prior to the first dose of the study intervention.
Trial design
Treatments tested in this trial
- ARC-02
- Rituximab
Treatment groups
140 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov